Hemogenyx Pharmaceuticals PLC Announces Recruitment of Second Patient for Clinical Trials
Hemogenyx Pharmaceuticals (LSE:HEMO) has announced the recruitment of its second patient for the clinical trial of HG-CT-1, their proprietary CAR-T cell therapy. The trial focuses on treating relapsed or refractory acute myeloid leukemia (R/R AML) in adult patients.
The company's scientific team will soon begin manufacturing HG-CT-1 for the second patient. This development represents a significant milestone in advancing a potential breakthrough treatment for AML patients with therapeutic options.
The recruitment progress suggests promising initial trial results, demonstrating the company's commitment to addressing urgent unmet medical needs in blood disease treatment.
Hemogenyx Pharmaceuticals (LSE:HEMO) ha annunciato il reclutamento del suo secondo paziente per la sperimentazione clinica di HG-CT-1, la loro terapia con cellule CAR-T proprietaria. La sperimentazione si concentra sul trattamento della leucemia mieloide acuta recidivante o refrattaria (R/R AML) in pazienti adulti.
Il team scientifico dell'azienda inizierà presto a produrre HG-CT-1 per il secondo paziente. Questo sviluppo rappresenta una tappa significativa nell'avanzamento di un potenziale trattamento innovativo per i pazienti affetti da AML con opzioni terapeutiche limitate.
I progressi nel reclutamento suggeriscono risultati iniziali promettenti della sperimentazione, dimostrando l'impegno dell'azienda nell'affrontare le urgenti esigenze mediche insoddisfatte nel trattamento delle malattie del sangue.
Hemogenyx Pharmaceuticals (LSE:HEMO) ha anunciado el reclutamiento de su segundo paciente para el ensayo clínico de HG-CT-1, su terapia con células CAR-T. El ensayo se centra en el tratamiento de la leucemia mieloide aguda en recaída o refractaria (R/R AML) en pacientes adultos.
El equipo científico de la empresa comenzará pronto a fabricar HG-CT-1 para el segundo paciente. Este desarrollo representa un hito significativo en el avance de un posible tratamiento innovador para los pacientes con AML que tienen opciones terapéuticas limitadas.
El progreso en el reclutamiento sugiere resultados iniciales prometedores del ensayo, demostrando el compromiso de la empresa para abordar las urgentes necesidades médicas no satisfechas en el tratamiento de enfermedades sanguíneas.
Hemogenyx Pharmaceuticals (LSE:HEMO)는 HG-CT-1, 그들의 독자적인 CAR-T 세포 요법에 대한 임상 시험의 두 번째 환자 모집을 발표했습니다. 이 시험은 성인 환자의 재발성 또는 불응성 급성 골수성 백혈병(R/R AML) 치료에 중점을 두고 있습니다.
회사의 과학팀은 곧 두 번째 환자를 위해 HG-CT-1을 제조하기 시작할 것입니다. 이 발전은 AML 환자들을 위한 잠재적인 혁신 치료법을 발전시키는 데 있어 중요한 이정표를 나타냅니다.
모집 진행 상황은 초기 시험 결과가 유망하다는 것을 시사하며, 혈액 질환 치료에서 긴급한 unmet medical needs를 해결하기 위한 회사의 노력을 보여줍니다.
Hemogenyx Pharmaceuticals (LSE:HEMO) a annoncé le recrutement de son deuxième patient pour l'essai clinique de HG-CT-1, leur thérapie par cellules CAR-T propriétaire. L'essai se concentre sur le traitement de la leucémie myéloïde aiguë récurrente ou réfractaire (R/R AML) chez les patients adultes.
L'équipe scientifique de l'entreprise commencera bientôt à fabriquer HG-CT-1 pour le deuxième patient. Ce développement représente une étape significative dans l'avancement d'un traitement innovant potentiel pour les patients atteints de AML avec des options thérapeutiques limitées.
Les progrès du recrutement suggèrent des résultats initiaux prometteurs de l'essai, démontrant l'engagement de l'entreprise à répondre aux besoins médicaux urgents non satisfaits dans le traitement des maladies du sang.
Hemogenyx Pharmaceuticals (LSE:HEMO) hat die Rekrutierung seines zweiten Patienten für die klinische Studie von HG-CT-1, ihrer proprietären CAR-T-Zelltherapie, bekannt gegeben. Die Studie konzentriert sich auf die Behandlung von rezidivierenden oder refraktären akuten myeloischen Leukämie (R/R AML) bei erwachsenen Patienten.
Das wissenschaftliche Team des Unternehmens wird bald mit der Herstellung von HG-CT-1 für den zweiten Patienten beginnen. Diese Entwicklung stellt einen bedeutenden Meilenstein bei der Weiterentwicklung einer potenziellen bahnbrechenden Behandlung für AML-Patienten mit begrenzten Therapiemöglichkeiten dar.
Der Fortschritt bei der Rekrutierung deutet auf vielversprechende erste Studienergebnisse hin und zeigt das Engagement des Unternehmens, dringende medizinische Bedürfnisse bei der Behandlung von Blutkrankheiten zu adressieren.
- Clinical trial progression with second patient recruitment indicates positive development momentum
- Manufacturing capabilities ready for immediate HG-CT-1 production for second patient
- Early clinical trial stage with only two patients recruited indicates long path to potential commercialization
Recruitment of Second Patient for HG-CT-1 Clinical Trial
LONDON, GB / ACCESS Newswire / March 17, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce the recruitment of the second patient for its clinical trial of HG-CT-1, its proprietary CAR-T cell therapy, for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) in adults. This marks a significant step forward in the Company's clinical development program and underscores the progress toward delivering a potentially life-saving treatment for AML patients with limited therapeutic options.
The manufacturing of HG-CT-1 for the second patient, carried out by the Company's team of scientists and quality control professionals, is scheduled to commence shortly.
Further updates on the clinical trial will be provided in due course.
Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:
"The recruitment of the second patient is indicative of the promising results of the clinical trial for HG-CT-1 thus far and represents another critical step in advancing HG-CT-1 as a potential breakthrough treatment for relapsed or refractory AML. This milestone reflects the dedication of our team and the strength of our science, bringing us closer to addressing an urgent unmet medical need."
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on ACCESS Newswire
FAQ
What is the current status of Hemogenyx's HG-CT-1 clinical trial for AML treatment?
What type of treatment is Hemogenyx developing for AML patients?
What stage is Hemogenyx's HG-CT-1 therapy currently in?
What patient population is targeted by Hemogenyx's HG-CT-1 therapy?
